Cancer Patient Lab Expert Webinar

Integrating Diverse Test Results for Personalized Cancer Treatment

Featuring: Joe Lennerz, MD, PhD, MSc

In short

Dr. Joe Lennerz, a diagnostic specialist at BostonGene, walks through how combining multiple cancer tests — such as next-generation sequencing, liquid biopsy, and immune profiling — gives a fuller picture of your tumor and opens doors to more targeted treatment options. The session is especially relevant for people with rare cancers, treatment-resistant disease, or those exploring later lines of therapy who want to understand how to build and use a comprehensive diagnostic profile.

  • •Ask your oncologist whether you have had next-generation sequencing of your tumor's DNA and RNA, a germline test for inherited gene changes, and a liquid biopsy — and whether results from these tests have been interpreted together.
  • •No single test tells the whole story; good decision-making relies on more than one data point, so ask your team how different test results are being cross-checked against each other.
  • •When choosing or evaluating your care team, look for a pathologist and oncologist who are current on multi-omics interpretation and can explain how a specific test would change your treatment options — not just order tests.
  • •If cost or insurance coverage is a barrier to advanced testing, ask your team directly about prior authorization support and financial assistance programs before assuming a test is out of reach.

Ask anything about this — free, no signup

Instant answers grounded in real guidelines, not the internet.

“Many groups have started implementing what are called ‘order sets’...

Meeting Summary

As cancer diagnostics evolve, patients and providers are faced with an overwhelming number of available tests—transcriptomics, proteomics, spatial and single-cell analysis, functional testing, liquid biopsies, and metabolomics, among others. The first challenge is determining which tests are necessary, a decision that changes rapidly as new tools become available.

The second challenge is integrating these diverse test results to form a coherent, actionable understanding of the disease. Without a structured approach, this complexity risks leading to fragmented decision-making and missed opportunities for precision care. Dr. Joe Lennerz, with his expertise in integrated diagnostics, is uniquely qualified to address these challenges.

He has experience as a Medical Director at Massachusetts General Hospital/Harvard Medical School and now as CSO at BostonGene, where he works on combining multimodal data to guide cancer treatment. Why is integrating diagnostic tests (DNA, RNA, immune system, imaging, …) for your unique cancer portrait important for your treatment decision-making?

•Gain deeper insights into your tumor biology

•Identify more precise treatment options and develop more personalized treatment strategies

•Understand your tumor heterogeneity and evolution

•Detect potential resistance mechanisms How should you gather and integrate information from multiple tests into your personalized, comprehensive disease profile and treatment implications?

•Build your portfolio of data: radiology, surgical pathology, traditional histomorphology, immunohistochemistry

•Extract clinical insights from your medical notes and tissue imaging

•Build in redundancy (with purpose); “orthogonality” is key - decision-making should rely on more than one data point

•Prepare your treatment timelines and responses

•Get “next-generation sequencing” genetic testing (whole exome sequencing - analysis of the protein coding regions) of the DNA and RNA of your cancer cells and your “germline” (analysis of DNA from your normal cells) to identify inherited changes in genes, particularly those related to an increased risk of cancer

•Get a liquid biopsy (typically a blood test, but can be saliva or other liquids)

•Get immune system profiling

•Use advanced analytics to correlate data across these different tests to inform your treatment strategies and understand your cancer's specific biological characteristics to go from rea real world data -> real world evidence What emerging tests could potentially inform your treatment decisions?

•Single-cell diagnostic technologies : can help distinguish tumor cells from normal cells, determine the origin and genetic constitution of the cells within the sample, provide detailed tumor microenvironment characterization, and identify mutation distribution across tumor cells

•Phylogenetic cancer maps: visualizations of the evolutionary history of tumors, including how they develop, spread, and respond to treatments, which can trace metastasis trajectories, understand how different tumor clones spread, detect resistance mutations, and provide insights into tumor heterogeneity How can you advocate for your access to the right tests for you?

•Choose a medical team (pathologist and oncologist) that leans into getting more testing for more comprehensive data and is current on the diagnostic technologies, have expertise in multi-omics data interpretation, and can provide contextual insights beyond raw test results, especially if you are considering later-line treatments or if you have a rare cancer

•Inquire about additional testing options; ask specific questions about molecular profiling, multi-omics testing, and whether additional testing could provide actionable insights for your treatment, such as targeted therapies or clinical trials; request a detailed explanation of how specific tests might inform treatment decisions, particularly for complex or treatment-resistant cancers

•Be prepared to discuss and pursue insurance coverage and potential financial assistance programs for advanced diagnostic testing

•Provide positive feedback when tests are helpful, such as sending a thank you note when a molecular test reveals an actionable mutation How can you learn more about how to navigate the rapidly changing landscape of cancer diagnostics for personalized treatment guidance?

•Join professional networks and discussion groups in oncology and molecular diagnostics; attend conferences and webinars; identify professional organizations like ASCO (American Society of Clinical Oncology) that provide reliable sources of information; read publications on “multi-omics” (diverse diagnostic tests) in cancer research; identify key experts in the field.

•Follow molecular diagnostic companies that specialize in comprehensive cancer testing

•Consult with oncologists who are using advanced diagnostic techniques

•Stay updated on the NCCN guidelines and emerging diagnostic technologies

•See our conversations with diagnostics experts:

•“The Latest

•• • • • •

•“Identifying the Most Effective Treatment on the Tumor Rather than Trying It Out on the Patient”

•Contact Michael Hensley at Michael.Hensley@bostongene.com. The information and opinions expressed on this website or platform, or during discussions and presentations (both verbal and written) are not intended as health care recommendations or medical advice by Cancer Patient Lab, its principals, presenters, participants, or representatives for any medical treatment, product, or course of action. You should always consult a doctor about your specific situation before pursuing any health care program, treatment, product or other course of action that might affect your health. For the video recording of this conversation, please see here. Meeting Notes KEYWORDS Integrated diagnostics, precision oncology, multi-omics, liquid biopsy, immune system profiling, tissue imaging, advanced analytics, treatment timelines, personalized diagnostics, companion diagnostics, phylogenetic cancer maps, single cell genomics, regulatory environment, clinical trials, oncologist collaboration. SPEAKERS Joe Lennerz (86%), Roger Royse (10%), Chris Apfel (3%), Michael Hensley (1%) CHAT CONTRIBUTORS Emma Shtiivelman, Saed Sayad, Russ Hollyer, Brad Power, Nahuel Villegas, Cheng Cui, Rick Davis, Chris Apfel, Dun Liang, Jamie Dempsey Barber, Roger Royse, Michael Dorsey, Ari Akerstein, Helen SUMMARY Dr. Joe Lennerz from BostonGene discussed integrated diagnostics and the challenges of navigating the complex landscape of cancer tests. He highlighted the importance of multi-omics approaches, including next-generation sequencing, liquid biopsy, and tissue imaging. Dr. Lennerz emphasized the need for comprehensive testing, especially in late-stage or rare cancers, and the importance of contextual interpretation. He also addressed the challenges of tissue procurement, the potential of single-cell DNA genomics, and the regulatory environment for companion diagnostics. The discussion included the practicality of multi-site omics testing and the role of oncologists in recommending these tests. OUTLINE Introduction and Speaker Background

•Dr. Joe Lennerz, CSO at BostonGene, discussed integrated diagnostics.

•He has experience as a medical director at Massachusetts General Hospital and Harvard Medical School.

•His work at BostonGene entails combining multimodal data to guide cancer treatment. Challenges in Precision Oncology

•Dr. Joe Lennerz discussed the complexity of the landscape of tests in precision oncology.

•He highlighted the constant changes in guidelines and approvals, and the daily practice challenges faced by providers and patients.

•He introduced the concept of integrating diverse test results to address these challenges.

•He mentioned the various technologies and use cases in cell-free or circulating tumor DNA, RNA, and biomarkers. BostonGene's Ecosystem of Tests

•Dr. Lennerz described BostonGene's ecosystem of tests, including next-generation sequencing, liquid biopsy, immune system profiling, and tissue imaging.

•He explained the different layers of data: raw data, process data, and advanced analytics.

•He emphasized the importance of orthogonality in decision-making and the need for more than one data point.

•He introduced the concept of moving from traditional diagnostics to multi-omics and the shift from profiling to portraits. Integration of Findings and Advanced Analytics

•Dr. Lennerz discussed the integration of findings and the shift from traditional diagnostics to multi-omics.

•He explained the concept of system integration and data complexity, using a graph to illustrate the landscape.

•He introduced the idea of moving from profiling to portraits, with more comprehensive multi-modality solutions.

•He demonstrated advanced analytics and the use of comprehensive solutions for drug developers and researchers. Right Test at the Right Time

•Dr. Lennerz introduced the concept of finding the right test at the right time, using a paradigm shift from EGFR identification to immune checkpoint inhibitor therapy.

•He discussed the complexity of finding the right test and the emergence of order sets for certain tumors.

•He explained the personalized diagnostic stage in precision oncology and the challenges of prior authorization and payment.

•He emphasized the importance of finding the right partners and collaboration, using an example of a small cell lung cancer classifier. Tissue Procurement and Low Tumor Content

•Getting enough tissue from pathologists remains an issue.

•Pancreatic cancer has low tumor content which makes it challenging to analyze such samples. Reproducibility and RNA Testing in Prostate Cancer

•For reproducibility of results, anchor points are important in multi-omics.

•Validating multi-omics data is challenging and quality metrics are needed.

•The actionability of RNA testing in prostate cancer is demonstrated by certain findings like TMPRSS2:ERG fusion.

•There is emerging evidence for the value of RNA sequencing in prostate cancer and the potential for RNA-based signatures. Correlating CNV (copy number variation) Data and Multi-Modality Biomarkers

•Correlating CNV data with biological consequences presents challenges and highlights the importance of having tumor-normal data.

•Orthogonal verification is needed and RNA data is important in determining oncogenic effects.

•Validating multi-modality biomarkers requires comprehensive data in early-phase trials.

•Emerging evidence can drive clinical utility and overcome the challenges of payer perspectives. Single Cell DNA Genomics and Phylogenetic Cancer Maps

•Chris Apfel asked about the relevance of single-cell DNA genomics in solid cancers, and Dr. Lennerz explained the technical challenges and potential benefits.

•Dr. Lennerz discussed the use of synthetic tissue algorithms like Cassandra to overcome the high cost of single-cell RNA Seq.

•Chris Apfel asked about the practicality of multi-site omics testing, and Dr. Lennerz explained the insights gained from multi-regional sampling.

•Dr. Lennerz discussed the work of Camila Naxalrova on tumor phylogenetics and the potential for phylogenetic cancer maps. Regulatory Environment and Practicality of Surveillance

•Roger Royse asked about updates in the regulatory environment and CDX regulation, and Dr. Lennerz discussed the challenges of proving analytical compatibility for rare events.

•Roger Royse asked about the practicality of surveillance for emergent ESR1 mutations, and Dr. Lennerz expressed uncertainty and the challenges of detecting mutations in circulating tumor DNA.

•Dr. Lennerz emphasized the importance of contextual interpretation in clinical testing and the need for meaningful application.

•Michael Hensley provided his contact information for clinical inquiries and emphasizes the importance of comprehensive testing in certain settings.

Full transcript

Roger Royse Welcome to this event by the Cancer Patient Lab. I'd like to introduce our speaker today, Dr. Joe Lennerz, who is the CSO at BostonGene. He's going to talk to us today about integrated diagnostics, and then also lead a discussion on the topic. He has experience as a medical director at Massachusetts General Hospital, Harvard Medical School, prior to becoming CSO at BostonGene.

At BostonGene he works in combining multimodal data to guide cancer treatment. Joe Lennerz 0:57 In the brief chat before we started the recording, we discussed integrating diverse test results. It is one of the key challenges or gaps. To address this today, I have tried to separate this into four things. ” “Precision oncology” is not only a buzzword, but it includes a plethora of solutions.

For example, just in the space of cell free or circulating tumor DNA, RNA, or biomarkers you see here, there are multiple different use cases just of that one technology. Providers as well as patients are faced with this diverse set of solutions when it comes down to practically looking at a certain challenge. On the one hand, the guidelines and approvals are constantly changing.

I show you here a part of a non-small-cell lung cancer NCCN guideline page. There are constantly new findings coming out in the literature. The daily practice sometimes looks like this, where individuals have to manage and navigate elements. How do we address this?

At BostonGene, we have many different solutions, and I want to show you that when looking at this, there are different, almost like cards in a Rolodex, that you can pull out when you want a certain lab technology to be applied to something to make it a little more concrete. I want to show you our “ecosystem of tests” that we have in a sort of interactive fashion. There are many different elements.

For example, in next gen sequencing, we perform whole exome sequencing at the DNA level, at the RNA level, and then, of course, whole genome sequencing, for example, or single cell RNA seq. And that forms one column of services. But as just outlined, there's liquid biopsy. We're very, very specialized on immune system ing Diverse Test Results for Cancer Patient Guidance” But as just outlined, there's liquid biopsy.

We're very, very specialized on immune system profiling and also on tissue imaging. In each of these there's a raw data layer, there's a process data layer, and then, of course, advanced analytics. I will come to that in a second. So for the discussion, I thought that navigating this landscape is that every single provider has to build their own portfolio of solutions.

They're sometimes built with a purposeful redundancy, for example, to be able to know if a marker is expressed in the cell that we want. Can we verify this at the DNA level, whether it's a somatic mutation or germline? Orthogonality is key, and decision-making is often relying on more than one data point. When we transverse this gap from real world data to real world evidence, this landscape becomes a resource.

If you're resourceful, you can turn this additional precision oncology or precision diagnostics into action. This is not just learning something to have CME (continuing medical education) points, but to become a better physician, better oncologist, and have actionable results. ” One thing that I thought of portraying to you is a shape shift in this landscape that we're currently witnessing.

What's shown in this very simple graph as a key message is, on the bottom, you see there's the system integration. What I mean with that is: is the workflow established, which would be closer to the left on the x axis, or do you need more administrative and IT resources that may not be as integrated as we wish? So that would go further to the right side. On the y axis is data complexity.

Traditional diagnostics would rank somewhat towards the bottom and to the left. Traditional diagnostics is established, so system integration is there, but the data complexity is not as high as we might want to have if you combine traditional diagnostics, let's say radiology, surgical pathology, traditional histomorphology, immunohistochemistry and maybe some molecular testing.

You might be in this intermodality range where, depending on the care pathway, you combine certain things together. If you combine them with intent and align it at the system integration, as well as the data complexity. Some people call it “integrated diagnostics”. The field is trying to move past that and talk about multi-omics. I can show you what that looks like, at least for BostonGene. I wanted to show you two examples.

One is that when we test clinical patients, we usually do a triple exome, which is DNA, RNA, and the germline. We take into account the treatment timelines and then current recommendations. There's a patient section, there's the context, the actual context of care in that particular patient. I'll show you that in a second. Then the actual findings, and then selected treatment options, and even a location-specific trial match.

That level of integration into one page report may not be sufficient to some really driven or research or cutting-edge oncologist, so we have a lot more pages, but we try to make it as concise as possible. We call the thing a “portrait”, rather than a “profile”, and I show you an image about that.

As an example, I want to show you that these abstract notes, clinical notes text, that many oncologists spend a lot of time making as concise as possible. We extract, using a Unified Medical Language abstraction, the concepts into these treatment timelines. These treatment timelines have one underlying principle: that simplicity is key.

This is not a timeline exactly, but the key events get an equidistant element so that you can get a very quick overview. This is, for example, used in tumor boards, etc. The other part that I want to point out is that we customize our reports to the setting.

As an example, on the left is the breast cancer report that I just showed you, and on the right is a lymphoma report, where jointly with some of our lymphoma experts, we restructured the layout to make it really personalized, not to the provider, but to the setting. So if you see a BostonGene report, and it looks completely different from cancer to cancer, that is caused by an optimization for that specific setting.

In other words, what we portray is that we switch from a profile, or tumor profile, to a portrait, to capture a bit more of what the cancer is about. We use advanced analytics. I want to demo this to you real quick. When we collaborate with our drug developer partners, pharma partners, or researchers, we offer a comprehensive set of solutions where you may have data, let's say, for example, DNA seq, RNA seq data, or imaging data.

These colors represent the frames in these figures.

And then, when looking over this large board, what you can see is that for certain elements, let's say someone wants to correlate protein expression status with transcripts or cell segmentation or classification of next to nearest neighbor analysis, you can click on the bottom left, and that will lead you to a peer-reviewed publication, including our team members that have access to the GitHub code, so that we can reconstruct the things very quickly.

The second part, when it comes to integration of findings, is we move from profiling to portraits, more comprehensive, multi-modality solutions, and we take the treatment context into account. I showed you the advanced analytics. ” That is, of course, a very complex and challenging question.

I want to introduce this through a paradigm shift that happened over the last decade, from an initial identification of EGFR, where multiple targeted therapies emerged from one single biomarker to a companion diagnostics approach that Foundation Medicine in 2017 has put forth, where a multitude of markers linked to a multitude of therapies, all the way to 2020, when an entirely different approach for precision diagnostics has emerged, where multiple biomarkers converge on immune checkpoint inhibitor therapy.

The change in landscape of companion diagnostics has now resulted in something, when I largely oversimplify this, that some cancers need very comprehensive genotyping, while other cancers primarily need just a certain set of markers or combinations. ” What I'm trying to say is that many groups have started implementing what is called “order sets”.

Here's an approach that was published by Dora Dias-Santagata in 2022, where an interdisciplinary team got together and decided, for certain tumors, certain test combinations are needed. Some people call that “order sets”. I wanted to give you a quick analogy. The right diagnostic at the right time, you could call it “R2D2”, and it might be really complicated to find a message in that.

What we realized is, when we do triple exome testing, we have the ability to add all kinds of signatures, all kinds of outputs, for the different tumor types. This has resulted in a cancer- specific combination of elements.

For example, a PAM50 signature in breast cancer (a 50-gene expression profiling test used to classify breast cancer into five molecular subtypes: Luminal A, Luminal B, HER2-enriched, Basal-like, and Normal-like), could produce bioinformatically to a prostate cancer or kidney cancer, but that wouldn't make any sense to classify based on these signatures.

This illustrates a flickering map of new signatures and new updates that would come out relatively quickly. So homologous recombination deficiency or DPYD testing is currently recommended in some, but not all, tumors. We've moved to a personalized diagnostic stage in precision oncology. That sounds promising, but the reality is that from order to a procedure and to payment there's a thing called “prior authorization”.

In clinical reality, it looks more like this. I want to emphasize that there's a financial sustainability problem The right test at the right time, of course, is what I just termed “personalized diagnostics”. Sometimes not doing testing can be actually meaningful. This weird letter cryptic code here means that prior auth testing denial appeal letter of medical necessity and medical exemption status claims.

It's probably something put here that we need to hold up, hold standards and order sets. Integrations that I want to end with, something about finding the right partners and collaboration. I want to show you something that is fairly unique, and in this group, it might actually hopefully resonate.

A few years ago, the laboratory around John Haymeck at MD Anderson published a small cell lung cancer classifier that distinguished four prognostic groups, and it had a huge promise that some groups, based on their biochemical biology, might respond differently to different therapies.

We collaborated, and the plan was to roll this out as a classifier, meaning we converted this into a clinical test, and then only in this case, two years later, we have a clear and CAP-approved test that is rolled out clinically and now serves as a phase two clinical trial enrollment stratifier in a Southwestern Oncology Group trial.

This level of collaboration, where certain data sets and literature is used to build a tool that is through public cohorts, as well as a tuning set that goes into the clinic and helps improve the standard of care, is very unique. As a final statement, this “find and collaborate” is things like this meeting here, where different groups, different stakeholders, come together and really collaborate.

One quick thing for those on the call who haven't met their pathologist, please make a call today. Call your pathologist and say, “Hey, I just want to introduce myself”, if you haven't done so.

I want to end by thanking you and then saying that these four points hopefully will form the basis for an interesting discussion today where navigating the landscape, the integration of findings, finding the right tests at the right time, and then finding and collaborating will hopefully help integrate diverse test results for cancer care guidance. I want to start off with something personal because I’m actually a customer.

I used your services two or three years ago, and at the time, the biggest challenge I faced was getting my tissue from a pathologist. It was incredibly difficult. Have things improved since then? Are major institutions now more familiar with testing and companies like BostonGene? We really had to go to extraordinary lengths to get my tissue back then, so I’m curious what the process looks like now.

Joe Lennerz

Tissue is the issue, and getting the right tissue at the right time. It definitely continues to be a problem, but the situation has improved. I can give you two or three reasons why it remains an issue. The value of molecular testing continues to be recognized. A common setting, for example, is with patients who have metastatic disease to the liver, where the oncology team is 100 percent certain it is breast cancer.

It looks like it. We have even seen this happen within the same institution. It might be that the pathologist feels compelled to work up the sample, cut through the sections, and perform additional immunohistochemistry. Some people call that waste tissue, done in an attempt to reconfirm the diagnosis, even when there was never a question that this was breast cancer.

Very frequently, we then end up without enough tissue for molecular genotyping, when the whole purpose of the biopsy was to perform molecular testing.

If the testing company is external, most commercial vendors now have tissue procurement teams, like the process described before by Roger, where someone has to make calls, request the right block, and yet still, you may receive a sample that does not contain a tumor, or you may get blank sections, and so on. I am describing this in detail because it was not, and still is not, always clear why this happens in practice.

If the oncologist indicates that the biopsy is specifically for identifying new therapies, that really helps. We have witnessed that clinician involvement can make a big difference. The second part is that many samples do not have enough tumor content. In pancreatic cancer, for example, it depends entirely on the size of the sample. The biopsy might be a fine needle aspiration or a smaller core needle.

Not every tumor is made up solely of tumor cells, and that often becomes another problem. Even after finally obtaining the tissue, there may not be enough tumor material on the slide to extract sufficient nucleic acids for testing. These are some of the elements that can be addressed by building strong relationships with laboratories and oncologists and by sharing with the team what the benefits are of the results.

Positive reinforcement definitely works. It does not cost much to thank a team for sending the blog which was really helpful and add that we identified an NTRK fusion and the patient now received therapy. Those small signals of gratitude can go a long way. What should you do if you have a tumor with low content—like in pancreatic cancer, where often less than 20 percent of the tissue is actually tumor and the rest is fibrous?

Can that still be analyzed? Joe Lennerz 19:55 We’ve been working on a solution that can go down to detecting as little as 1 to 2 percent tumor content. The main challenge is bringing something like that into clinical use, because it introduces some liability, and the validation process becomes difficult. While we can analytically detect variants at very low frequencies, the question is, how do we reliably validate that?

You can design a certain validation approach, but as of now, we do not offer this clinically. We’re still working on it. Is it always analytically valid? Can we always claim it's clinically valid? Probably not. So we would likely need to include a disclaimer. In tumors like pancreatic cancer, where there is often a common driver mutation, the presence of that known alteration can help confirm that tumor is present.

This starts to resemble the challenges of liquid biopsy testing where if you do not see a v variant, is it truly absent, or did we just fail to detect it? That continues to be a challenge. We do have some strategies to work around that, including immune profiling, but it remains a complex issue. How do you ensure the reproducibility of your results?

Joe Lennerz

With multi-omics, one of the key elements is that you need certain anchor points in one modality that can be replicated in another modality. Let me give you an example. Take pancreatic cancer. Suppose you identify a KRAS G12C mutation at the DNA level, and now you want to perform expression profiling using RNA sequencing data.

A basic sanity check would be to confirm that the same KRAS G12C variant is also present in the RNA-seq dataset. Another common integration for reproducibility and data integrity is checking whether the HLA genotype is the same between germline testing and somatic data. These anchor points across datasets serve as linkers to ensure the findings are reliable. They are absolutely essential.

” Without these checks, things can get very tricky especially when you're working with gene expression profiling and copy number assessments. It is something to verify and be mindful of. Is RNA testing actionable with regard to prostate cancer? Are any therapies FDA-approved for RNA results? Joe Lennerz 23:00 There are currently no FDA-approved therapies.

However, there are certain findings from RNA sequencing in prostate cancer that are really important. One of them is the TMPRSS2:ERG gene fusion ( a common genetic alteration in prostate cancer that involves the fusion of two genes, TMPRSS2 and ERG). You can detect that fusion using DNA sequencing by identifying a breakpoint, but the other part is capturing the actual TMPRSS2-ERG fusion transcript, which you can identify through RNA sequencing.

That gives you confirmation that it is cancer. This fusion is very common in prostate cancer. There are a few individual case reports suggesting it might occur in bladder cancer, but I highly doubt that. I haven’t seen anything convincing but if it does happen, it would be exceptionally rare, even within the same genitourinary region. Why this is important is because prostate cancer is such a long and protracted disease.

If, a few years later, a lesion is found, say, in the retroperitoneum or the spine, you can reassess whether it still harbors the same fusion. That allows you to establish a phylogenetic relationship between the original tumor a and the new lesion. The second finding that is important or of interest relates to a paper published a few years ago in the New England Journal of Medicine by Emmanuel Antonarakis from Johns Hopkins.

It described an alternative splice form of the androgen receptor, called AR-V7, in the context of castration resistance. This is particularly interesting because the androgen receptor, which is composed of different exons, can, under the pressure of castration resistance, undergo alternative splicing to a cryptic exon, which I believe is cryptic exon three. That specific isoform is referred to as AR-V7.

This element cannot be reliably detected using DNA analysis alone, because it is a splicing event, so you need RNA sequencing to detect it. Now, the data is not entirely clear on whether AR-V7 always appears in the setting where next-generation anti- androgens like abiraterone and enzalutamide fail to work, but identifying these alternative splice isoforms is one of the key emerging applications of RNA sequencing.

Many researchers are currently working on expression-based signatures in prostate cancer. As most in the community know, Gleason grading continues to be a key element in distinguishing high-grade from low- grade prostate cancer. However, that approach is old, even though it is still considered reliable, it is also highly variable between observers.

Many groups are now working on RNA-based signatures in the hopes of providing more objective prognostic indicators. To summarize, I would call this emerging evidence for the utility of RNA sequencing in prostate cancer. Even the detection of AR-V7 itself is somewhat under question.

There has been some work on whether it can be detected in blood, and whether it can be used for treatment monitoring, almost as a second independent marker alongside PSA. I must say, I have not seen anyone offering that routinely. Internally, we have done some work suggesting that anything over eight reads showing splicing to the cryptic exon seems to be a reliable indicator that AR-V7 is present but that is highly assay-dependent.

You can quantify it and some tumors show extremely high AR- V7 expression, while others only show a low presence. So it is likely, at least in part, a subclonal event. Roger Royse 27:13 5. do you correlate CNV data (copy number variation is when the number of copies of a particular gene varies from one individual to the next) with biological consequences. How many extra copies of a given oncogene can you link with an oncogenic effect?

Joe Lennerz

First of all, CNV stands for copy number variation. Copy number variations can be either gains or losses, so we refer to them as copy number gains (CNG) or copy number losses (CNL). These are the two main types of copy number variants. Work by John Frady, published in Nature Genetics, illustrated that in our normal cells, one element contributing to genetic variability is copy number alterations and these can be entirely normal.

Certain genes or genomic regions vary naturally from person to person in terms of how many copies exist. That is very important to keep in mind when describing copy number alterations, because if you only analyze the tumor without the corresponding normal tissue, you might mistakenly interpret a normal variation as a tumor-specific gain. This is why setting a cutoff for CNVs should always be done in the context of that specific patient.

For example, in fluorescent in situ hybridization (FISH- a lab technique that uses fluorescent probes to detect specific DNA sequences in cells or tissue samples), you can sometimes literally see fluorescent dots for each gene copy. In some tumor cells, these dots are too numerous to count, and it becomes clear that the gene is amplified. This is typically the case for EGFR amplification in glioblastoma or HER2 amplification in breast cancer.

But defining a cutoff for what constitutes amplification is complicated. There are two main factors to consider. First, if a tumor has what appears to be low-level amplification, it might actually be high-level amplification that is diluted by a high number of non- tumor or inflammatory cells. In other words, is the copy number truly low within tumor cells, or are normal cells without amplification diluting the signal?

To address this, we rely on two key approaches. The first is to always analyze both tumor and normal tissue. Triple exome sequencing can be used in these situations which gives us a reference normal sample. That allows us to precisely determine the copy number in the tumor and helps identify things like heterozygous loss, loss of heterozygosity, genotype loss, or even subtle gains.

The second approach is to confirm whether the copy number change actually has an oncogenic effect. can look at the transcriptome to see whether the transcript of that gene is also enriched. This type of orthogonal verification or cross-checking between DNA and RNA is critical, though it depends on the specific gene and the biological context.

One of the key examples of this is in mesothelioma and a few other cancers, where loss of CDKN2A and MTAP is becoming more important, especially at that locus. Having tumor, germline, and RNA data together makes interpretation easier, but it remains a challenging area.

When data from multiple modalities are used to develop a biomarker, could there be challenges to validate because of the potential requirement data from these modalities for each patient in the study? Joe Lennerz 31:44 This brings up the question of whether simplicity is good enough. If you already have a biomarker that serves as a response predictor or a secondary endpoint, then a simple approach might seem sufficient.

However, the opposite viewpoint arises when planning a large-scale, multi-million dollar study. In such cases, gaining additional data, even if it only improves prediction slightly, becomes a form of risk mitigation. Given the complexity of regulatory planning, preclinical data, and early-phase transitions, it makes sense to gather as much insight as possible from each sample.

For instance, if you only run a DNA panel and later realize that expression profiling or subtyping could have added value such as in breast cancer, you may miss an opportunity. We advocate for collecting a maximum amount of data early, especially when it can inform whether a treatment response is linked to a particular molecular signature.

We have seen through collaborations with pharmaceutical partners that early-phase monitoring using multi-modal data can be incredibly insightful. At that point in a trial, having all relevant data in context is valuable not just for assessing the current therapy but also for informing subsequent lines of treatment. Often, patients on trials progress and move to new therapies, so understanding the molecular landscape can help guide those decisions.

In this setting, the argument is not about cost, but about utility and timing. However, in routine clinical practice, the situation is different. From a payer or CMS perspective, we cannot yet justify comprehensive testing like exome or genome sequencing for everyone, as the clinical utility is still being established.

This is why it is important to distinguish between trial-based research use and everyday clinical application as they follow very different paradigms. Validating biomarkers developed from multiple data modalities remains one of the biggest challenges. Regulatory requirements are rigorous, and not all signals remain strong enough to pursue long-term.

In drug development, where timing is crucial, having to go back and collect new data could slow progress. A more efficient approach might be to use multi-modal strategies for the first cohort (10 to 20 patients) to identify responders and non-responders, analyze those findings in real time, and apply an adaptive trial design moving forward.

In later stages, the need for all modalities may decrease depending on the early findings and how the trial evolves. There is a question about a single cell DNA genomics platform. While it has been used in hematological cancers, such as blood cancers, it has not yet been widely applied to solid tumors. The question is whether this approach is useful in solid cancers or if the relevance of the information is limited.

Joe Lennerz

Yes, single cell RNA sequencing means you dissociate the cells, sequence them, and obtain data from every single cell. That creates an extremely rich dataset. Some technologies also allow spatial resolution, so you can see where mutations are located. More data is not always better as it can create new challenges but this is now possible.

In liquid or hematologic malignancies, since the cells are already separated, single cell analysis is more technically feasible using tools like flow cytometry or sorting. But these technologies have also been applied to solid tumors. At BostonGene, we invested effort into sequencing 25,000 cell lines and used that to build a synthetic tissue by combining different cell types. We call this algorithm Cassandra.

It emulates single cell resolution from bulk RNA Seq data, helping overcome the high cost of single cell sequencing. We’ve shown in multiple publications the added value such as tumor microenvironment characterization and distinguishing expression patterns in tumors. From a clinical standpoint, this is still considered emerging evidence. We have ongoing trials with groups like the Parker Institute and others to support this.

Why hasn’t this been widely adopted is because it requires significant computing power and expert bioinformatics teams to manage the data. That level of infrastructure is mostly limited to research labs at large academic centers or within industry. So the slower adoption is due to technical and resource-related challenges.

My question is actually related to Mission Bio’s single cell DNA platform, not the 10x Genomics RNA-seq that everyone usually talks about. DNA, in a sense, is more stable that it doesn’t change as dynamically and it reflects the status of different clones. Joe Lennerz 40:14 It’s definitely an area of interest especially because DNA-level data provides key insights when analyzed at the single cell level.

You can assess things like ploidy (copy number alterations) and clonality whether the tumor has the same mutation, like BRAF, in every cell. Together, ploidy and clonality help evaluate tumor purity. If we can resolve this both spatially and at the single cell level, it might help overcome issues related to tumor purity, ploidy, and clonality. That would allow for a much clearer assessment.

That said, I haven’t yet seen a strong clinical use case for this beyond improving the accuracy of mutation detection. This relates to the earlier discussion on pancreatic cancer, where tumor content can be limited. Single cell genomics could help distinguish between normal cells, likely fibroblasts and actual tumor cells, allowing for a much more accurate assessment of true mutations.

It also enables us to quantify whether there is a single clone or multiple clones and identify the co-localization of mutations within those clones. This helps build a clearer picture of the tumor’s sensitivity profile. To add to that, is it worth performing omics analysis at multiple sites?

Joe Lennerz

I worked for years with Camila Naxalrova, a colleague here in Boston, whose career has focused on tumor phylogenetics and multi-regional sampling. The level of insight gained from studying tumor dynamics led us to coin the term "clading", where certain clones metastasize to specific regions.

Camila has published extensively on whether metastases spread through lymph nodes before reaching organs, or if the primary tumor seeds directly to other sites. By creating phylogenetic maps and conducting multi-regional sampling of both primary and metastatic tumors including in cases like peritoneal carcinomatosis, we have seen clear trajectories of how different clones spread. These clades remain clinically overlooked.

While the current clinical focus is on typing, staging, grading, and now genotyping, we believe clading should be added if we could simply sample more. This research has now extended to melanoma, breast cancer, colorectal cancer, and cholangiocarcinoma. The latter is especially heterogeneous, with multiple clones within the liver that can be traced as they metastasize.

Clinically, one of the most important implications is understanding whether resistance mutations found in peripheral blood reflect the full complexity of the tumor. Re-biopsy and multi-regional sampling offer powerful biological insights, though when and how to apply them in clinical practice is still being explored. Are there any updates in our regulatory environment and CDX regulation? Joe Lennerz 45:06 Yes, that is a personal favorite of mine.

I can share a brief statement we put out in a white paper, developed jointly with a large consortium and Friends of Cancer Research, which reflects something I feel strongly about. Many of the major genetic companion diagnostic targets like BRAF, EGFR, etc have already been found, and the remaining ones represent increasingly smaller subsets. Take NTRK fusions, for example.

I have only seen a few cases in my decades of practice as they’re extremely rare. We are essentially dealing with orphan diseases now, like lung cancer with an NTRK fusion or a pediatric tumor with the same. Given how rare these are, I wish the regulatory landscape would relax the requirements for proving analytical compatibility. Right now, it’s a one-size-fits-all approach.

But in orphan diseases, maybe you don’t need 30, 40, or 50 cases to validate a diagnostic; perhaps just three positives and three negatives, confirmed with an approved orthogonal diagnostic, would be enough. There are other considerations too, but I believe easing these overly stringent requirements for already validated companion diagnostics would significantly improve access. That’s my regulatory wish. Could you comment on the AZ SERENA-6 trial?

I can’t quite pronounce it, but you probably can. It’s about surveillance for emergent ESR1. How practical or sustainable is this kind of monitoring in patient care? Joe Lennerz 47:37 I am aware of the issue, and I know it’s quite controversial. But honestly, I don’t feel confident arguing either for or against it. I think this is more a question for a breast oncologist. I know that detecting emerging ESR1 mutations can be very tricky.

If peripheral blood is used for this, we run into a challenge I often see with circulating tumor DNA: if a mutation is detected, that’s fine but if it’s absent, we can’t tell if it’s truly not there or if we just didn’t detect it. Overcoming that uncertainty is a real challenge in this context, and I haven’t seen a reliable solution yet. That’s all I can say on the topic. Who is working on phylogenetic cancer maps?

Because we found very high correlation of primary metastatic tumors for local spread, while correlation with metagenic spread was still about 50% Joe Lennerz 48:54 The collaborator that I mentioned is Camila Naxalrova, and she works with a lot of different laboratories, so I know that at least three, four other groups are working on it. I would call it as an emerging field.

For a hypothetical high-risk patient who wants to predict micrometastases and the progression from hormone-sensitive prostate cancer (HSPC) to castration-resistant prostate cancer (CRPC), what type of testing would you recommend? Joe Lennerz 50:13 It's a very tricky area and still emerging.

The question points toward RNA expression profiling– based assays, and while there are a few commercial solutions available, I’m not sure of their current standing within the NCCN guidelines. I would recommend checking those guidelines and the expert panel's latest recommendations for a more consensus-driven approach. If that doesn't yield clear direction, the next step would be to dive into the literature and evaluate the supporting evidence.

How do patients typically find these tests and identify when it's relevant to get them? How do they find you? Joe Lennerz 51:17 Most of the patients who find us do so through public webinars. However, 95 percent of our work comes through oncologists. The oncologists who refer patients to us usually appreciate that we go beyond standard results. We typically don’t test first-line therapy patients or newly diagnosed non-small-cell lung cancer cases.

Instead, we work with patients in the third or fourth line of treatment, those with extremely rare sarcomas, or in later stages where no standard of care exists which we call orphan diseases. ” We've helped in some of those cases. To be clear, we don’t find something for everyone, but in specific situations, we’ve identified findings that significantly changed treatment outcomes.

Yes, this type of testing is more expensive and isn’t always covered by insurance, but when used in the right context, we’ve seen remarkable results. Comprehensive testing isn’t meant for everyone as it has to be applied meaningfully. It’s interesting to hear that oncologists are actually recommending this as I didn’t realize that was the case. I had assumed it was more up to the patient to ask for it. Could you talk a bit about the cost?

I’m guessing insurance typically doesn’t cover it, right? Joe Lennerz 53:21 Yes, that’s correct. It depends as our financial assistance program is based on household income and is quite competitive, similar to other vendors in this space. But I think the key point to understand is that it’s not just about identifying a finding.

As I mentioned in the treatment timeline during my presentation, what’s really important is placing that finding in the context of the patient’s care. For example, you might see a report that identifies an NTRK fusion and suggests a specific inhibitor; it's often just a standard paragraph dropped into many reports. We don’t do that. Instead, we look at whether the patient has already received that therapy.

If they have, we wouldn’t recommend it again. The finding might still be present, but its relevance changes based on the care timeline. That kind of contextual interpretation is something many providers really appreciate, especially given how hard it is to keep up with emerging data and new complexities. And even when we don’t find a major actionable target, we include additional pages that might still help identify something meaningful.

BostonGene operates as a clinical testing service, using the same billing codes as other companies in the space, such as Tempus and Caris. They bill both insurance and Medicare. com. Joe Lennerz 55:36 For patients wondering about additional testing options, it is important to discuss this directly with their healthcare provider, as they guide immediate care decisions.

” can often open up valuable conversations about further diagnostic or treatment avenues. CHAT DISCUSSION 00:31:56Emma Shtivelman: Q for Dr Lennerz: is BG planning to offer tumor microdissection for tissues with low (<20%) tumor content? In a couple of cases I know, analysis of any sort was not possible because of the nature of samples (few tumor cells present) 00:34:06saed.

c) CHAT DISCUSSION 00:31:56Emma Shtivelman: Q for Dr Lennerz: is BG planning to offer tumor microdissection for tissues with low (<20%) tumor content? sayad:With all these sources of uncertainty, how do you ensure the reproducibility of your multiomics results? 00:35:47Russ:Is RNA testing actionable WRT prostate cancer? Are any therapies FDA approved for certain RNA results?

00:38:52Brad and Mary Power: Antonarakis has led a discussion with our community. 00:39:12Russ:AR-V7: is it digital (there/not there) or analog? Can it be predicted? 00:39:34Nahuel Villegas: How you correlate CNV data (in particular amplifications) with biological consequences? in other words, how many extra copies of a given oncogene can you reliably link with an oncogenic effect?

00:39:49Cheng Cui:When data from multiple modalities are used to develop a biomarker, could there be challenges to validate b/c of the potential requirement of data from these modalities for each patient in the study? 00:43:32Rick Davis:Back in the day (ca 2014), AR-V7 was a big issue and JH offered AR V7 testing. It was thought to interfere with enzalutamide and cause it t fail Today we never hear of it.

Peeps just take enz and if it fails they move on. Failure is usually determinable within 90 days. 00:45:00Dr. Chris Apfel:Mission Bio has a single cell DNA genomics platform allowing to characterize the colocalization of mutations in various clones. Looks like there is interest in hematological cancers, but not solid tumors. Should this not also be useful for lung, ovarian, and many other solid cancers?

Or is the clinical relevance of that information actually quite limited? 00:49:16Dun Liang:What updates would you like to see in CDx regulation, if any? 00:54:03Jamie Dempsey Barber: Along the same lines, is it worth doing omics on multiple sites of metastasis or primary and metastasis given the tumor heterogeneity and evolution? Is more information a good thing?

00:59:03Dun Liang:Could you comment on AZ’s SERENA-6 trial for camizestrant, where surveillance for emergent ESR1 is being implemented? How practical or sustainable is this surveillance in patient care? " Link isn’t working for me. " ? " Link not working for me either.

01:00:51Roger Royse:A companion diagnostic is a medical device, often an in vitro diagnostic (IVD), which provides information that is essential for the safe and effective use of a corresponding drug or biological product.

Companion diagnostics can: identify patients who are most likely to benefit from a particular therapeutic product, identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. 01:01:13Dr. Chris Apfel:Dr.

Lennerz, who is working on these phylogenetic cancer maps? g. ovarian), while correlation with hematogenic spread was still ~50% (colorectal to lung) in our functional precision oncology platform. " Hypothetical high risk HSPC PCa patient If the patient would like to predict micro-mets and HSPC->CRPC developement what type of testing would you recommend? 01:03:48Cheng Cui:Need to drop now - Thank you, Joe for sharing your insights!

This is very helpful!! 01:04:05Mr. Michael:Reacted to Check out Pete Nelso... with " " 👍 01:04:14Mr. naxerova... with " " 👍 01:04:19Mr. Michael:Reacted to Yup - expired try t... org/news- releases/704968 01:04:29Mr. " Are SNPS important for tumor therapy/aggressiveness? 01:04:56ari akerstein:I’ll ask a very basic question: how do patients typically find these tests / identity when it’s relevant to get them?

01:05:45Rick Davis:One more Q - talk about commercial accessibility and pricing please 01:07:03ari akerstein:So provider-led. I wonder what % of patients would benefit vs. do actually benefit . How big is the gap. 🙂 01:07:24Helen:Thank you for your recommendation. In Europe/ France do you have recommendations for testing, for rare ovarian cancer that is not well known or understood.

Other than conventional treatments I’ve already had, gene and tissue testing at the initial onset, what other tests here that you see can be useful. I get limited guidance of ‘what else’ I can do especially in line of precision testing. hensley: BostonGene Tumor Portrait is the standard of care clinical NGS test for MD Anderson in advanced cancers 01:10:00Helen:Thank you!!

Want to learn more about your specific case?

Upload your medical records and ask Navis questions tailored to your diagnosis.